
Atopic Dermatitis
Latest Content
Latest Videos

Shorts

More News

Chronic hand eczema affects roughly 5% of adults each year, exacts most of its toll at work, and is not simply atopic dermatitis of the hands.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.

Telehealth care for atopic dermatitis matched in-person outcomes in a study, signaling a scalable option for underserved patients.

The FDA's first new sunscreen ingredient approved in nearly 3 decades is set to reshape the US market. Here is what dermatologists need to know.

Expert insights reveal how to spot inflammation in deeply pigmented skin and use new biologics and melasma therapies to reduce dyspigmentation.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.

Discover how the SkinTracker app enhances AD management through remote assessments, offering convenience and accuracy comparable to in-person visits.

Research highlights the need for diverse data on drug efficacy in atopic dermatitis to address barriers to treatment for patients with skin of color, notes Elain Siegfried, MD.

Roflumilast cream 0.05% gains FDA approval for young children, offering a safe, effective treatment for mild to moderate atopic dermatitis.

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.







